The Herpes
Simplex Virus Treatment Global Market Report 2024 by The Business Research
Company provides market overview across 60+ geographies in the seven regions -
Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the
Middle East, and Africa, encompassing 27 major global industries. The report
presents a comprehensive analysis over a ten-year historic period (2010-2021)
and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Herpes Simplex Virus Treatment Market:
https://www.thebusinessresearchcompany.com/report/herpes-simplex-virus-treatment-global-market-report
According to The Business Research Company’s Herpes Simplex Virus Treatment
Global Market Report 2024, The herpes simplex virus treatment market size has
grown strongly in recent years. It will grow from $2.24 billion in 2023 to
$2.39 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be
attributed to increased prevalence of hsv infections, antiviral medications
development, clinical research and drug approvals, patient education and
awareness, global efforts for std prevention.
The herpes simplex virus treatment market size is expected to see strong growth
in the next few years. It will grow to $3.1 billion in 2028 at a compound
annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be
attributed to advancements in antiviral therapies, focus on preventive
measures, potential vaccine development, telemedicine and remote consultations,
global health initiatives. Major trends in the forecast period include
incorporation of nanotechnology, telemedicine for remote consultations, natural
and herbal therapies, strategies for neonatal herpes prevention, antiviral drug
resistance monitoring.
The surge in the prevalence of sexually transmitted infections is expected to
propel the growth of the herpes simplex virus treatment market going forward.
Sexually transmitted diseases (STDs) or sexually transmitted infections (STIs)
refer to an illness brought on by an infection with specific bacteria, viruses,
or other microorganisms that can be spread from one person to another through
blood, semen, vaginal secretions, or other body fluids during sexual
intercourse with an infected partner. Herpes simplex virus or HSV treatment is
primarily used to treat sexually transmitted illnesses, including urethritis,
cervicitis, and infections that cause genital ulcers. For instance, in April
2023, according to the Center for Disease Control and Prevention, a US-based
national public health agency, the number of sexually transmitted diseases
(STDs) in the USA increased between 2020 and 2021, reaching a total of more
than 2.5 million. Further, syphilis cases in the US increased by 32% from
133,954 in 2020 to 176,713 in 2021. Therefore, the surge in the prevalence of
sexually transmitted infections is driving the growth of the herpes simplex
virus treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10691&type=smp
The herpes simplex virus treatment market covered in this report is segmented –
1) By Type: Herpes Simplex Virus-1 Infection, Herpes Simplex Virus-2 Infection
2) By Drug Type: Acyclovir, Valacyclovir, Famciclovir, Other Drugs
3) By Route Of Administration: Oral, Injection, Topical
4) By Vaccine: Simplirix, Other Vaccines
5) By Distribution Channel: Hospital Pharmacies, Drug store, Retail Pharmacies,
Online Providers
Rising innovations in HSV treatment are a key trend gaining popularity in the
herpes simplex virus treatment market. Major companies operating in the herpes
simplex virus treatment market are focused on innovating new treatments and
drugs to sustain their position in the market. For instance, in October 2022,
Replay Therapeutics, a US-based genome writing company, launched Eudora, its
first HSV gene therapy company focused on retinal eye disease. It is the first
product firm Replay created to use synHSVTM, a high-payload-capacity HSV
delivery vector. Within disease-area-specific product firms, Replay's unique
corporate structure distinguishes between the development of technological and
medicinal products. The first of Replay's four synHSVTM gene therapy product
firms, Eudora, use big DNA gene therapy to treat monogenic brain, skin, and
muscle illnesses. The other three companies use small-molecule DNA gene
therapy.
The herpes simplex virus treatment market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment